PL2857039T3 - Środek terapeutyczny lub środek profilaktyczny na otępienie - Google Patents

Środek terapeutyczny lub środek profilaktyczny na otępienie

Info

Publication number: PL2857039T3
Authority: PL; Poland
Prior art keywords: agent; dementia; prophylactic; therapeutic agent; therapeutic
Prior art date: 2012-05-31

Application number

PL13797290T

Other languages

English (en)

Inventor

Hiroshi Mori

Takami Tomiyama

Yoichi Matsumoto

Hiroshi Eguchi

Yuichi Kunori

Original Assignee

Osaka City University

Teijin Pharma Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-31

Filing date

2013-05-30

Publication date

2020-05-18

2013-05-30 Application filed by Osaka City University, Teijin Pharma Limited filed Critical Osaka City University

2020-05-18 Publication of PL2857039T3 publication Critical patent/PL2857039T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

PL13797290T 2012-05-31 2013-05-30 Środek terapeutyczny lub środek profilaktyczny na otępienie PL2857039T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2012124336		2012-05-31
PCT/JP2013/065090 WO2013180238A1 (ja)	2012-05-31	2013-05-30	認知症治療剤又は予防剤
EP13797290.7A EP2857039B1 (en)	2012-05-31	2013-05-30	Therapeutic agent or prophylactic agent for dementia

Publications (1)

Publication Number	Publication Date
PL2857039T3 true PL2857039T3 (pl)	2020-05-18

Family

ID=49673425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13797290T PL2857039T3 (pl)	2012-05-31	2013-05-30	Środek terapeutyczny lub środek profilaktyczny na otępienie

Country Status (30)

Country	Link
US (3)	US20150183854A1 (pl)
EP (2)	EP3662931B1 (pl)
JP (3)	JP5971659B2 (pl)
KR (2)	KR102208283B1 (pl)
CN (1)	CN104602708B (pl)
AR (1)	AR091218A1 (pl)
AU (2)	AU2013268364B2 (pl)
BR (1)	BR112014029566A2 (pl)
CA (1)	CA2875205C (pl)
CY (1)	CY1122530T1 (pl)
DK (1)	DK2857039T3 (pl)
ES (2)	ES2973070T3 (pl)
HR (1)	HRP20192267T1 (pl)
HU (1)	HUE046919T2 (pl)
IL (1)	IL235899B (pl)
LT (1)	LT2857039T (pl)
ME (1)	ME03587B (pl)
MX (1)	MX361128B (pl)
MY (1)	MY172458A (pl)
NZ (1)	NZ630536A (pl)
PH (1)	PH12014502669B1 (pl)
PL (1)	PL2857039T3 (pl)
PT (1)	PT2857039T (pl)
RS (1)	RS59802B1 (pl)
RU (1)	RU2657438C2 (pl)
SG (2)	SG10201805410XA (pl)
SI (1)	SI2857039T1 (pl)
TW (2)	TWI700296B (pl)
WO (1)	WO2013180238A1 (pl)
ZA (1)	ZA201409186B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012106363A2 (en)	2011-01-31	2012-08-09	Intellect Neurosciences Inc.	Treatment of tauopathies
EP2709728B1 (en) *	2011-05-20	2019-01-23	Oligomerix, Inc.	Tau protease methods of use
SI2857039T1 (sl) *	2012-05-31	2020-03-31	Osaka City University	Terapevtsko sredstvo ali profilaktično sredstvo za demenco
WO2014008404A1 (en)	2012-07-03	2014-01-09	Washington University	Antibodies to tau
TW202136296A (zh) *	2014-06-27	2021-10-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗-tau抗體
US20190224339A1 (en) *	2016-04-29	2019-07-25	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
JP6785372B2 (ja) *	2016-09-30	2020-11-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
KR20190134997A (ko)	2017-02-17	2019-12-05	데날리 테라퓨틱스 인크.	항-tau 항체 및 이의 사용 방법
JOP20180014A1 (ar) *	2017-02-27	2019-01-30	Teijin Pharma Ltd	جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
IL270971B2 (en)	2017-05-30	2024-06-01	Teijin Pharma Ltd	Anti-igf-i receptor antibody
SG11202002575UA (en)	2017-10-02	2020-04-29	Merck Sharp & Dohme	Chromane monobactam compounds for the treatment of bacterial infections
TWI750419B (zh)	2017-10-16	2021-12-21	日商衛材R&D企管股份有限公司	抗tau抗體及其用途
EP3778631A4 (en)	2018-04-06	2022-01-05	Teijin Pharma Limited	Spns2 neutralizing antibody
JP7340794B2 (ja) *	2018-07-04	2023-09-08	学校法人愛知医科大学	タウのスプライシングを制御するアンチセンスオリゴヌクレオチド及びその用途
CN110028583B (zh) *	2019-05-07	2020-09-11	温州医科大学	抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
JP7429404B2 (ja) *	2019-08-06	2024-02-08	慶應義塾	タウ関連疾患モデルの製造方法
WO2021065306A1 (ja)	2019-09-30	2021-04-08	ニプロ株式会社	血液試料を検体とするタウタンパク質検出方法
US20230137434A1 (en) *	2020-03-19	2023-05-04	Vascular Biosciences	CAR Peptide for Improved Coronavirus Survival
CA3183835A1 (en)	2020-06-25	2021-12-30	Jeanne E. Baker	High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko)	2022-09-15	2025-05-19	보이저 테라퓨틱스, 인크.	타우 결합 화합물
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS587390B2 (ja)	1975-03-11	1983-02-09	ツキシマキカイカブシキガイシヤ	ア−クヨウセツホウホウ
JP3587390B2 (ja)	1994-03-17	2004-11-10	タカラバイオ株式会社	リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
WO1997034145A1 (fr) *	1996-03-13	1997-09-18	Mitsubishi Chemical Corporation	Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
US20080199471A1 (en) *	2002-03-01	2008-08-21	Bernett Matthew J	Optimized cd40 antibodies and methods of using the same
US8012936B2 (en) *	2006-03-29	2011-09-06	New York University	Tau fragments for immunotherapy
US20070280935A1 (en) *	2006-04-07	2007-12-06	Bernd Bohrmann	Antibody that recognizes phosphorylated peptides
WO2007149293A2 (en) *	2006-06-16	2007-12-27	Envivo Pharmaceutical, Inc.	Transgenic flies expressing tau and amyloid precursor fragment
UA107571C2 (xx) *	2009-04-03	2015-01-26		Фармацевтична композиція
EP4218794A3 (en)	2009-06-10	2023-09-13	New York University	Immunological targeting of pathological tau proteins
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2012106363A2 (en) *	2011-01-31	2012-08-09	Intellect Neurosciences Inc.	Treatment of tauopathies
TR201102696U (tr) *	2011-05-27	2011-06-21	Turhal Sal�H	Bağlantısız hareketli ürün reklam standı.
SI2857039T1 (sl) *	2012-05-31	2020-03-31	Osaka City University	Terapevtsko sredstvo ali profilaktično sredstvo za demenco
JOP20180014A1 (ar) *	2017-02-27	2019-01-30	Teijin Pharma Ltd	جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه

2013
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending

Also Published As

Publication number	Publication date
AU2018200413B2 (en)	2019-10-17
IL235899B (en)	2019-03-31
PT2857039T (pt)	2020-01-07
JP2018111716A (ja)	2018-07-19
KR20150027098A (ko)	2015-03-11
DK2857039T3 (da)	2019-12-16
CN104602708A (zh)	2015-05-06
ES2973070T3 (es)	2024-06-18
CY1122530T1 (el)	2021-01-27
JPWO2013180238A1 (ja)	2016-01-21
CN104602708B (zh)	2021-11-30
ES2763361T3 (es)	2020-05-28
SI2857039T1 (sl)	2020-03-31
RU2014153099A (ru)	2016-07-20
US20220340646A1 (en)	2022-10-27
MX2014014187A (es)	2015-06-04
RS59802B1 (sr)	2020-02-28
KR102208283B1 (ko)	2021-01-26
PH12014502669A1 (en)	2015-02-02
US20200148753A1 (en)	2020-05-14
LT2857039T (lt)	2020-03-10
WO2013180238A1 (ja)	2013-12-05
KR102133610B1 (ko)	2020-07-14
EP2857039A4 (en)	2015-08-26
IL235899A0 (en)	2015-01-29
EP3662931B1 (en)	2023-12-06
US20150183854A1 (en)	2015-07-02
JP2016147902A (ja)	2016-08-18
TW202041532A (zh)	2020-11-16
SG10201805410XA (en)	2018-08-30
AU2013268364B2 (en)	2018-02-08
JP5971659B2 (ja)	2016-08-17
EP3662931A1 (en)	2020-06-10
HK1210031A1 (en)	2016-04-15
AR091218A1 (es)	2015-01-21
BR112014029566A2 (pt)	2017-07-25
CA2875205A1 (en)	2013-12-05
ME03587B (me)	2020-07-20
ZA201409186B (en)	2015-12-23
HRP20192267T1 (hr)	2020-03-20
RU2657438C2 (ru)	2018-06-13
PH12014502669B1 (en)	2020-02-19
SG11201407878VA (en)	2015-01-29
AU2013268364A1 (en)	2014-12-18
EP2857039B1 (en)	2019-11-20
TWI777183B (zh)	2022-09-11
AU2018200413A1 (en)	2018-02-08
TWI700296B (zh)	2020-08-01
EP2857039A1 (en)	2015-04-08
CA2875205C (en)	2021-07-20
HUE046919T2 (hu)	2020-04-28
KR20200029619A (ko)	2020-03-18
MY172458A (en)	2019-11-26
NZ630536A (en)	2017-03-31
MX361128B (es)	2018-11-28
JP6406678B2 (ja)	2018-10-17
JP6620829B2 (ja)	2019-12-18
TW201410705A (zh)	2014-03-16

Publication	Publication Date	Title
ZA201409186B (en)	2015-12-23	Therapeutic agent or prophylactic agent for dementia
PL3153144T3 (pl)	2019-07-31	Urządzenie izolacyjne
SG11201501173SA (en)	2015-05-28	PI3Kδ INHIBITOR
EP2913053A4 (en)	2016-05-25	THERAPEUTIC OR PROPHYLACTIC AGENT FOR TUMOR LYING SYNDROME
GB201217439D0 (en)	2012-11-14	Combination therapy
SG11201500074XA (en)	2015-03-30	Safety cabinet
EP2554541A4 (en)	2013-10-09	THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA
GB201207305D0 (en)	2012-06-13	Therapy
PL399419A1 (pl)	2012-12-17	Sposób wytwarzania 4-metoksydihydrochalkonu
PL399418A1 (pl)	2012-12-17	Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A (en)	2016-08-31	Process for making 5-fluoro-h1-pyrazoles
PL2677104T3 (pl)	2018-09-28	Szafka bezpieczeństwa
PT2861118T (pt)	2018-07-25	Conjunto sanitário
EP2879707A4 (en)	2016-05-11	COMBINATION THERAPY
GB2502527B (en)	2018-07-18	Plumbing apparatus
GB2505665B (en)	2016-07-27	Residual range system
GB201220529D0 (en)	2012-12-26	No details available
GB201214234D0 (en)	2012-09-19	Prophylactic therapy
GB2499038B (en)	2014-05-07	Safety apparatus
GB201220253D0 (en)	2012-12-26	Plumbing apparatus
GB201211543D0 (en)	2012-08-15	Combination therapy
PL2861904T3 (pl)	2019-01-31	Ulepszone urządzenie instalacji wodociągowej
PL2677099T3 (pl)	2019-05-31	Szafka bezpieczeństwa
HU229987B1 (en)	2015-04-28	Process for the preparation of pyrimidinyl-piperazines
GB201213825D0 (en)	2012-09-19	Damper-device for bouncing-device